(S)-3-(Boc-氨基)-2-哌啶酮 | 92235-39-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-3-(Boc-氨基)-2-哌啶酮
• 中文别名: (S)-3-Boc-氨基哌啶-2-酮；(S)-2-哌啶酮-3-氨基甲酸叔丁酯；S)-2-哌啶酮-3-氨基甲酸叔丁酯；(S)-3-Boc-氨基-2-哌啶酮
• 英文名称: (S)-tert-butyl (2-oxopiperidin-3-yl)carbamate
• 英文别名: (S)-3-(Boc-amino)-2-piperidone；tert-butyl N-[(3S)-2-oxopiperidin-3-yl]carbamate
• CAS: 92235-39-7
• 化学式: C₁₀H₁₈N₂O₃
• 分子量: 214.265
• InChiKey: SSBSATYPIISWFD-ZETCQYMHSA-N

物化性质

• 熔点：
  203-205 °C
• 沸点：
  405.6±34.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl (s)-2-oxopiperidin-3-ylcarbamate
Synonyms: (S)-3-(Boc-amino)-2-piperidone

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl (s)-2-oxopiperidin-3-ylcarbamate
CAS number: 92235-39-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H18N2O3
Molecular weight: 214.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-3-(Boc-氨基)-2-哌啶酮 在 palladium on activated charcoal 氢气 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 25.0 ℃ 、206.84 kPa 条件下， 生成 (S)-2-(3-(叔丁氧羰基氨基)-2-氧代哌啶-1-基)乙酸
  参考文献：
  名称：

  新型，选择性和口服可生物利用的凝血酶抑制剂的设计，合成和进化：掺有P3-P4内酰胺磺酰胺基团的P1-精氨酸衍生物。

  摘要：

  DOI：

  10.1021/jm960572n
• 作为产物：
  描述：

  Boc-L-鸟氨酸 在 碳酸氢钠 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以62%的产率得到(S)-3-(Boc-氨基)-2-哌啶酮
  参考文献：
  名称：

  具有构象限制的环状二肽的蛋白质合成

  摘要：

  我们已经合成了几种构象受限的二肽类似物作为掺入蛋白质的可能底物。这些包括由 2,4-二氨基丁酸、鸟氨酸和赖氨酸的 Boc 衍生物形成的三种环状二肽，分别具有 5、6 和 7 元内酰胺环。这些二肽用于激活抑制性 tRNA 转录物，后者是通过体外转录制备的。使用改良的大肠杆菌与先前描述的核糖体相比，这些激活的抑制性 tRNA 能够将三种环状二肽并入二氢叶酸还原酶 (DHFR) 的 18 和 49 位。抑制产量随着内酰胺环大小的增加而增加，并且被发现以 3.4 到 8.9 的抑制产量进行5、6 和 7 元内酰胺二肽在两个不同蛋白质位点的百分比。7 元内酰胺更容易掺入，促使我们通过 1-乙基-3-(3-二甲氨基丙基)碳二亚胺 (EDCI) 介导的氨基酸环化制备两种 7 元环状酰肼（4和5），具有选择性在其侧链中保护肼官能团。与内酰胺二肽、酰肼二肽4 相同和5可用于激活相同的抑制性 tRNA 转录本并将环状二肽整合到

  DOI：

  10.1016/j.bmc.2020.115780

文献信息

• Diphenylsilane as a coupling reagent for amide bond formation
  作者：Morgane Sayes、André B. Charette

  DOI：10.1039/c7gc02643a

  日期：——

  A simple procedure for amide bond formation using diphenylsilane as a coupling reagent is described. This methodology enables the direct coupling of carboxylic acids with primary and secondary amines, releasing only hydrogen and a siloxane as by-products. Only one equivalent of each partner is needed, providing a more sustainable amidation method producing minimal wastes. This methodology was also

  描述了使用二苯基硅烷作为偶联剂形成酰胺键的简单程序。这种方法可以使羧酸与伯胺和仲胺直接偶联，仅释放出氢和作为副产物的硅氧烷。每个合作伙伴只需要一个等价物，即可提供一种可持续性更高的酰胺化方法，从而减少浪费。通过添加Hünig碱（DIPEA）和4-二甲基氨基吡啶（DMAP），该方法还扩展到肽和内酰胺的合成。
• [EN] 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS 5-AZAINDAZOLE ET MÉTHODES D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014001377A1

  公开（公告）日：2014-01-03

  5-Azaindazole compounds of Formula (I), including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式（I）的5-氮杂吲唑化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式（I）化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Direct Synthesis of Amides from Carboxylic Acids and Amines Using B(OCH₂CF₃)₃
  作者：Rachel M. Lanigan、Pavel Starkov、Tom D. Sheppard

  DOI：10.1021/jo400509n

  日期：2013.5.3

  range of amines. In most cases, the amide products can be purified by a simple filtration procedure using commercially available resins, with no need for aqueous workup or chromatography. The amidation of N-protected amino acids with both primary and secondary amines proceeds effectively, with very low levels of racemization. B(OCH2CF3)3 can also be used for the formylation of a range of amines in good

  B(OCH 2 CF 3 ) 3由易得的B 2 O 3和2,2,2-三氟乙醇制备，是一种有效的试剂，可用于多种羧酸与多种胺的直接酰胺化。在大多数情况下，可以使用市售树脂通过简单的过滤程序纯化酰胺产物，无需进行水处理或色谱法。N-保护的氨基酸与伯胺和仲胺的酰胺化有效进行，外消旋化水平非常低。B(OCH 2 CF 3 ) 3 通过二甲基甲酰胺的转酰胺基作用，也可用于一系列胺的甲酰化反应，收率良好至极好。
• [EN] SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF<br/>[FR] AMIDES DE L'ACIDE ADIPIQUE SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012125622A1

  公开（公告）日：2012-09-20

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1 C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中A是一个五至八元的单环或一个九至十二元的双环杂环环，如本文所进一步定义；Y是S、CH2或CH；Z是CH或N；R7和R9是氢或（C1-C6）烷基；R2是（C1-C6）烷氧基、羟基、氰基、（C1-C6）烷基、卤素或三氟甲基；r和s为0、1或2；R1和R3如本文所进一步定义。这些化合物是NPY4受体的激动剂、部分激动剂和/或调节剂，可用于治疗和预防肥胖、食物摄入和其他由NPY4受体调节的疾病和症状。
• Lactam inhibitors of factor Xa and method
  申请人：——

  公开号：US20020025957A1

  公开（公告）日：2002-02-28

  Lactam inhibitors are provided which have the structure 1 including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 10a , 10 11 and R 12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

  提供了具有以下结构的内酰胺抑制剂 1 ，包括其药用可接受的盐及其所有立体异构体，以及其前药酯，其中n为1至5；和 和R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 ，R 10 ，R 10a ，10 11 和R 12 如本文所定义。这些化合物是因子Xa的抑制剂，因此可用作抗凝剂。还提供了一种用于治疗与血栓相关的心血管疾病的方法。